Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results

Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve effectiveness AF ablation within a shorter procedure time. We aimed compare and safety PVI between this vHPSD mode (90W/4s) conventional index-guided (up 40W/indexed). Methods This single-center, retrospective, observational study enrolled 148 AF, referred for December 16, 2019 July 29, 2022. In 77 procedures (mean age: 59.7±12.0 years; 61.0% male; 74.0% paroxysmal), used (vHPSD-group), 71 58.1±11.6 70.4% 67.6% paroxysmal) were treated index (AI-group). The assessed recurrence 3- 6-months after ablation. outcomes also included amount opioids administered during incidence treatment-emergent adverse events. Additionally, procedural factors, such as total time, fluoroscopy time radiofrequency application compared groups. Results At 3 months, found recur 14.29% (11/77) vHPSD-group 30.99% (22/71) AI-group (p=0.02). 6 18.31% (13/71) reported 32.73 % (18/55) (p=0.09). There no difference events two groups (3.9% vs. 2.8%; p=1.00). One severe event (a cerebral vascular accident) observed vHPSD-group. mean dose remifentanil be lower vHPSD-based (p<0.0001). associated (p<0.0001), Conclusions suggests that vHPSD-quided equally effective safe reference short-term clinical observation Also, may allow reduce dosage analgesics significantly procedures.